catalyst

L1 Capital claimed the top two spots in Livewire's FY26 Australian equity fund rankings. We went behind the scenes to find out why.

In a wide-ranging discussion, L1 Capital provided an update on four current positions that it continues to see opportunity in.

Visibility is the theme this month, with brokers backing stocks that have clear catalysts for growth and re-ratings.

L1 Capital's James Hawkins recently conducted a webinar discussing the Catalyst Fund. Here we summarise the highlights of the session.

LTR Pharma is a clinical-stage pharmaceutical company, commercialising a world first in erectile dysfunction, Spontan, a PDE5 nasal spray.

Activist investing continues to rise in prominence in Australia. In this wire James Hawkins of L1 Capital shares his insights on the space.

In this episode, Elston's Justin Woerner and LSN Capital's Nick Sladen analyse five stocks with possible share price-moving catalysts.

Leveraging expertise for expansive growth

Game changing catalysts typically drive share price re-ratings for companies. So which companies have major developments on the horizon?

In this episode, PM Capital's Paul Moore and Antipodes' Jacob Mitchell analyse five stocks making waves on the global stage this year.